Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2004

01-02-2004 | Meeting abstract

The presence of deiminated fibrin in the synovial membrane is not specific for rheumatoid arthritis

Authors: S Chapuy-Regaud, M Sebbag, D Baeten, C Clavel, F De Keyser, G Serre

Published in: Arthritis Research & Therapy | Special Issue 1/2004

Login to get access

Excerpt

Autoantibodies to deiminated (citrullinated) forms of the α and β chains of fibrin (AhFibA), also known as antifilaggrin autoantibodies (AFA), are the most specific serological markers of rheumatoid arthritis (RA). Deimination is critical in generating the AhFibA epitopes and, in the synovial tissue (ST), deiminated fibrin is their major antigenic target. Existence of fibrin deimination specifically in RA patients could explain why the AhFibA response is RA specific. …
Metadata
Title
The presence of deiminated fibrin in the synovial membrane is not specific for rheumatoid arthritis
Authors
S Chapuy-Regaud
M Sebbag
D Baeten
C Clavel
F De Keyser
G Serre
Publication date
01-02-2004
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 1/2004
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1062

Other articles of this Special Issue 1/2004

Arthritis Research & Therapy 1/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.